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BASIC RESEARCH
CYCLOSPORIN A REDUCES AIRWAY MUCUS
SECRETION AND MUCOCILIARY CLEARANCE IN
RATS
Rogerio Pazetti, Paulo Manuel Pego-Fernandes, Otavio Tavares Ranzani, Edwin
Roger Parra, Geraldo Lorenzi-Filho, Fabio B. Jatene
Pazetti R, Pego-Fernandes PM, Ranzani OT, Parra ER, Lorenzi-Filho G, Jatene FB. Cyclosporine A reduces airway mucus
secretion and mucociliary clearance in rats. Clinics. 2007:62(3):345-52.
PURPOSE: To assay the effects of cyclosporin A on mucus secretion from goblet cells and on mucociliary transport in situ in
rats.
METHODS: Twenty-one male Wistar rats were assigned to 3 groups: control (n = 5), saline (n = 8), and cyclosporin A (n = 8).
After 30 days of drug therapy, the rats were killed, and the lungs were removed from the thoracic cavity. Mucus samples were
collected, and the transport rate was evaluated in vitro using a bullfrog palate model. Mucociliary transport was timed in situ by
direct view of particles trapped on the mucus moving across the respiratory tract. Finally, the amount of stored mucins in the
goblet cells of the respiratory epithelium was measured.
RESULTS: Drug dosage measurements showed that cyclosporine blood concentration at the moment the rats were killed was
1246.57 ± 563.88 ng/mL. The in vitro transport rate was significantly lower (P < .001) in the cyclosporin A-treated group. Also,
the in-situ mucociliary transport rate was decreased in all cyclosporin A-treated animals when compared to the saline group (P =
.02). Mucus quantity measurements showed a significant decrease on both acid (P = .01) and neutral (P = .02) mucus production
from goblet cells in the animals submitted to cyclosporin A therapy. The correlation between the percentage of total mucus and in
vitro transport rate was positive and significant (r = 0.706, P < .001), as was the correlation between the percentage of total mucus
and the in situ mucociliary transport rate (r = 0.688, P = .001).
CONCLUSION: This study shows that cyclosporin A plays an important role in the impairment of the mucociliary clearance in
rats by reducing both acid and neutral mucus production from goblet cells and causing a decrease in the mucociliary transport
velocity.
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INTRODUCTION
Mucociliary clearance is the principal nonspecific defense
mechanism of the airways. In the upper airways, particles
and other inhaled materials are entrapped in mucus and trans-
ported by ciliary motion, termed mucociliary transport, from
the lungs. Under normal circumstances, efficient mucociliary
transport is the result of the coordination of 3 airway epi-
thelial cell functions: quantitative and qualitative mucus se-
cretion, ciliary beating, and fluid transport.1
Respiratory mucus secretion is an important element
in mucociliary transport. This mucus is composed of 1%
by weight of salts and other dialysable components; 0.5%
to 1% free protein; a similar proportion of carbohydrate-
rich glycoproteins, also called mucins; and 95% or more
of water.2
The chemical composition of the respiratory mucus
glycoproteins is suspected to influence the formation of the
molecular network of mucus, thereby altering its
rheological properties. Pharmacological interference in
mucociliary transport is caused by a new class of drugs used
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for immunosuppressant therapy, but the mechanism for this
mucociliary effect has not been established.3 Cyclosporin
A (CsA) is one of the most important immunosuppressants
used in lung transplantation.4–6
Although the molecular events have not yet been
completely defined, some studies indicate that CsA
blocks the initial stages of lymphocyte activation,7,8 in-
hibiting the production of interleukin-2 and other
lymphokins.9,10 Theoretically, the mechanism of action
of CsA includes an influence on cytoplasmatic calcium,
which is an essential component for normal cellular
function.11 Some authors have reported a direct correla-
tion between CsA-induced cytotoxicity and changes in
mitochondrial enzyme activity.12,13 Cyclosporin A has
also the ability to interact with receptors within the nu-
cleus to inhibit genetic transcription of proteins secreted
by fibroblasts, endothelial cells, macrophages, and
monocytes.14 Moreover, CsA has many side effects, such
as nephrotoxicity, hepatotoxicity, gum hypertrophy, hy-
pertension, and a high incidence of lymphoma. The side
effects are usually dose-dependent, and are reversed fol-
lowing dose reduction.15–17
Because mucociliary clearance is inhibited in patients
receiving immunosuppressants such as CsA, we also con-
sidered it relevant to assess whether CsA acts on the gob-
let cell activity causing impairment either on quantity or
quality of the respiratory mucus.
METHODS
Twenty-one male Wistar rats (300 ± 25 g) were assigned
to 3 groups as follows: control (n = 5), intact animals; sa-
line (n = 8), animals that received saline solution (0.9%
NaCl, Baxter) subcutaneously for a 30 days period; and
CsA (n = 8), animals that received Cyclosporin A
(SANDIMMUN®, 50 mg/mL, Novartis, Switzerland) at a
dose of 10 mg/kg/day, subcutaneously, for 30 days.
The animals were maintained according to the “Guide
for the Care and Use of Laboratory Animals,”18 and the pro-
tocol was approved by our institutional Ethics Committee.
After 30 days of drug therapy, the rats were anesthetized
with pentobarbital (50 mg/kg, intraperitoneally) and killed
by exsanguination, according to the “Report of the Ameri-
can Veterinary Medicine Association Panel on Euthana-
sia.”19
In the CsA group, before exsanguination, blood sam-
ples were collected from abdominal aorta, and drug dos-
age measurements were made by fluorescence polarization
immunoassay FPIA with the TDxFLx® system.
After euthanasia, the lungs were removed from the tho-
racic cavity, and an incision was performed along the tra-
cheobronchial tree. Mucus samples were collected by plac-
ing a soft-bristled brush against the pulmonary airway and
removing the brush once it was covered with sufficient
mucus for analysis.20
The in vitro transport rate was evaluated by using a bull-
frog (Rana catesbeiana) palate model. Briefly, the trans-
port velocity of the mucus sample placed on a frog palate
was determined with the aid of a stereomicroscope fitted
with a micrometer scale. Three to five measurements of the
transport rate of the rat mucus samples were taken to mini-
mize measurement variability, and the average transport
rate of each one was normalized to the transport rate for
collected endogenous frog mucus; the results were ex-
pressed as relative speed (rat/frog).21,22
After mucus sample collection, the ventral wall from
tracheobronchial tree was removed to expose the respira-
tory epithelium. Then, the tissue was placed and analyzed
in a light microscope (Olympus, BX50, Tokyo, Japan) fit-
ted with a micrometer scale, and in situ mucociliary trans-
port was timed by direct view of particles trapped on mu-
cus moving across the respiratory tract.
Finally, to measure the amount of stored mucins in the
respiratory epithelium, serial sections (3µm thick) from
main stem bronchi were cut with a microtome and stained
with periodic acid-Schiff (PAS) and alcian blue (AB) se-
quences to demonstrate neutral and acidic mucosubstances,
respectively.23
All slides were blinded, and an Image-Pro Plus 4.1 for
Windows (MediaCybernetics, Silver Spring, MD), running
on a microcomputer connected to a digital camera (JVC
TK-C1380 color video camera; Victor Company of Japan,
Yokohama, Japan) coupled to an optical microscope (Leica
DMR; Leica Microsystems, Bensheim, Germany) was used
for the measurements.
Ten fields per slide were evaluated at a final magnifi-
cation x400. In each field, we quantified the mucus per-
centage per respiratory epithelium area as follows:
mucus =
mucus area × 100
epithelium area →[%]
Data were analyzed using a Statistic Package for So-
cial Sciences for Windows (SPSS 10.0 version) program.
Results are expressed as mean ± standard deviation (SD),
and a P value less than .05 was considered significant. We
used a 1-way ANOVA test to verify the interference and
interaction of the analyzed factors. Comparisons between
groups were performed using Bonferroni post-tests. To
evaluate the correlation between the variables, Pearson’s
correlation coefficient and the linear regression model were
used.24
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RESULTS
Drug dosage measurements showed that the blood con-
centration of CsA at the moment the rats were killed was
1,246.57 ± 563.88 ng/mL (M ± SD).
The in vitro transport rate was significantly less (P < .001)
in the CsA group than in the saline group (Figure 1). Also,
the in situ mucociliary transport rate was decreased in the CsA
group compared to the saline group (P = .02) (Figure 2).
Mucus quantity measurement results showed a sig-
nificant decrease (P = .002) of total mucus from goblet cells
in the animals submitted to CsA therapy (Figure 3). When
compared to the saline group, the CsA group presented
lower amounts of acid and neutral mucus, and this differ-
ence was statistically significant (P < .05). In pair-wise
comparisons between the saline and CoA groups, signifi-
cant differences were found for acid mucus (P = .01) and
neutral mucus (P = .02), respectively.
The correlation between the percentage of total mucus
and the in-vitro transport rate was positive and significant
(r = 0.706, P < .001) (Figure 6). Similar results were found
in the correlation of the percentage of total mucus in the
respiratory epithelium and the in-situ mucociliary transport
rate (r = 0.688, P = .001) (Figure 7).
Figures 8 and 9 are representative illustrations of the
amount of acid and neutral mucus in respiratory epithelium
from the saline and CsA groups, respectively.
DISCUSSION
Many studies have been done with the aim of better un-
derstanding the various factors involved with CsA therapy,
such as its structure, administration route, toxicity, immu-
nosuppressant effects, and its relationship with other im-
munosuppressant agents.25
Figure 1 - In vitro transport rate from rats treated with saline or cyclosporin
A for 30 days. There was significant difference between groups (P < .001).
Figure 2 - In situ mucociliary transport rate of rats treated with saline or
cyclosporin A for 30 days. There was significant difference between groups
(P = .02).
Figure 3 - Percentage of mucus in respiratory epithelium from rats treated
with saline or cyclosporin A for 30 days. There was significant difference
between groups (P = .002).
Figure 4 - Percentage of acid mucus in respiratory epithelium from rats
treated with saline or cyclosporin A for 30 days. There was significant
difference between groups (P = .01).
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Due to its lipophilic nature, CsA is highly dissolved in
organs and quickly delivered into tissues and plasmatic
stores.26,27 In the blood, 90% is linked to plasma proteins,
and 10% to granulocytes and lymphocytes.28,29 More than
70% of the administered CsA is processed by the liver and
excreted together with the bile; up to 10% of its metabolites
can be eliminated through the renal route.30 In humans, ab-
sorption of the drug occurs through the small intestine, and
its half-life is around 6 to 9 hours.31 In human transplanta-
tion, CsA is frequently administered orally and intrave-
nously. However, in the rat experimental model, the intra-
muscular and subcutaneous routes are preferable.
The dosage of CsA is variable according to whether pa-
tients are undergoing organ transplant procedures, or are
different responses in the rejection process.25 In this study,
we tested a dosage that is commonly used in humans im-
mediately after transplantation. We administered CsA daily
(10 mg/kg of body weight, subcutaneously), and the mean
serum levels we found (1,246 ng/mL) were similar to those
of others who tested the pharmacokinetics of the drug in
rats.25 Many studies have reported that this is an effective
and nontoxic dose that it is also well tolerated by rats, pro-
ducing a constant serum concentration.32
To assess the influence of CsA on the transportability
of the mucus samples, we used an in-vitro model of mu-
cus depleted frog palate, since the bullfrog’s palate is lined
with a pseudostratified epithelium, similar to that found in
human conductive airways.21 Rubin and co-workers22 sug-
gested that bullfrog mucus has viscoelastic properties that
are similar to those of normal mammalian respiratory mu-
cus. This technique has been widely used as a means of
defining the inherent transportability of mucus, independ-
ent of systemic ciliary function. Respiratory mucus must
have ideal physical properties (viscosity and elasticity) to
allow cilia penetration, to receive their transmitted energy
and to provide effective mucus transport along the ciliated
epithelium.33 Due to the cross-linking of glycoproteins, the
rheological behavior of mucus is described as viscoelastic,
having characteristics of both a liquid and a solid.34
The relative proportions of elasticity and viscosity are
important in describing how a material such as mucus be-
haves when it is subjected to external forces. The ratio of
viscosity to elasticity is also an important determinant of
mucociliary clearance. Increasing viscosity at constant elas-
ticity in a model system caused a pronounced decrease in
the mucociliary transport rate.35 Although this phenomenon
has not been observed for intact mucus from healthy ani-
mals, it has been seen in pathological human material.36
In this study, we observed that mucus samples collected
Figure 5 - Percentage of neutral mucus in respiratory epithelium from rats
treated with saline or cyclosporin A for 30 days. There was significant
difference between groups (P = .02).
Figure 6 - Relationship between in vitro transport rate and percentage of
total mucus in respiratory epithelium from rats treated with saline or
cyclosporin A for 30 days. There was significant difference between groups
(r = 0.706; P < .001).
Figure 7 - Relationship between in situ mucociliary transport and percentage
of total mucus in respiratory epithelium from rats treated with saline or
cyclosporin A for 30 days. There was significant difference between groups
(r = 0.688; P = .001).
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from the CsA group showed a significantly decreased trans-
port rate when compared with samples collected from the
saline group. Moreover, the analysis of the in-situ
mucociliary clearance rate also showed significant impair-
ment of the transport speed in the CsA group. These re-
sults show that CsA changed the quality of mucus by al-
tering either its viscosity or elasticity, or both.
The perfect function of mucociliary transport depends
on an interaction among various factors, such as an intact
ciliated epithelium with synchronized ciliary beating, an
adequate amount of mucus with ideal viscoelastic proper-
ties, and the adequate composition and size of the
periciliary fluid layer, which is determined mainly by the
quality and quantity of mucous glycoproteins or mucins
present in the mucus.37
The respiratory tract mucus has characteristics that allow
its interaction with ciliated cells, such as an adequate depth
of the periciliary layer (sol phase) and an ideal mechanical
behavior. If the periciliary layer is too thick, cilia will not be
able to reach the gel phase, and therefore will not be able to
push it. Conversely, when the periciliary layer is thin, cilia
will be permanently in contact with the gel phase, which in
turn will hinder the recovery movement of cilia.38 In both situ-
ations, there is some degree of impairment of the mucus trans-
port rate, which may result in mucostasis, a characteristic
shared by several airway diseases.39
The concept that alterations in mucus volume impact
mucus hydration, and thus the rheology of mucus result-
ing in an increase in susceptibility to infection in cystic
fibrosis airways, continues to gain credence.40 A marked
decrease in the airway surface liquid volume in cystic fi-
brosis bronchial explants in-vitro reflects the abnormal ion
transport properties of cystic fibrosis airway epithelia in
vivo.41 Similar behavior as well as increased amounts of
mucus and altered mucus transport and mucus adhesion to
airway surfaces is observed in-vivo in mice that overexpress
the subunit of the epithelial sodium channel, ENaC.42
The sol phase composition of the mucus is controlled
by a complex mechanism of absorption and secretion of
liquids from several ionic channels of the apical membrane
Figure 8 - Quantity of acid mucus in respiratory epithelium from saline (A)
and cyclosporin A (B) groups.
Figure 9 - Quantity of neutral mucus in respiratory epithelium from saline
(A) and cyclosporin A (B) groups.
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of epithelial cells. In addition, the ionic channels probably
regulate the hydration degree of the gel phase, thus modu-
lating its rheological properties.34
To assess whether CsA also affects the amount of mu-
cus secretion from goblet cells, we quantified both acid and
neutral mucus in respiratory epithelium. Airway mucins are
thought to be derived from periodic-acid-Schiff (PAS)-posi-
tive secretory granules (“mucous” granules) found in 2
different cell types in the airway: goblet cells of the sur-
face epithelium and mucous cells of the submucosal
glands.43 Since airway mucins are a mixture of mucins se-
creted from the 2 different cell types, it has been practi-
cally impossible to purify goblet cell mucins from airway
mucus.44 Therefore, the structure of airway goblet cell
mucins was initially defined based mainly on cytochemis-
try in which the secretory granules are stained with vari-
ous dyes, depending on the degree of acidity of the
mucins.45,46 Such studies indicated that goblet cell mucins
contain neutral, sialylated, and sulphated sugars, and that
the distribution of these mucins varies greatly depending
on animal species. Biochemical characterization of the epi-
thelial mucin was made possible only after successful iso-
lation and culturing of these cells.43 Secretory mucins are
stored in secretory granules and released at the apical sur-
face in response to mucin secretagogues, while membrane-
tethered mucins are integrated into the cell membrane.47
Our results show that CsA causes a significant decrease
in both acid and neutral mucin production from goblet cells
and thus could potentially play a significant contributory
role in the complex mechanisms of mucociliary transport
and clearance. Further studies are necessary to investigate
the exact cellular mechanisms of CsA action on goblet
cells, either on mucin gene expression or on ionic chan-
nels of the apical membrane.
RESUMO
Pazetti R, Pego-Fernandes PM, Ranzani OT, Parra ER,
Lorenzi-Filho G, Jatene FB. Ciclosporina A reduz a
secreção de muco das vias aéreas e o transporte mucociliar
de ratos. Clinics. 2007;62(3):345-52.
OBJETIVO: Avaliar os efeitos da ciclosporina A sobre a
produção de muco das células caliciformes e sobre o
transporte mucociliar in situ de ratos.
MÉTODOS: Vinte e um ratos machos Wistar foram
distribuídos em três grupos: Controle (n=5), Salina (n=8)
e Ciclosporina A (n=8). Após 30 dias de terapia, os ratos
foram mortos e os pulmões removidos da cavidade torácica.
Amostras de muco foram coletadas e a medida da
transportabilidade in vitro foi realizada através de um
modelo de palato de rã. A velocidade do transporte
mucociliar foi medida através da observação direta do
deslocamento de partículas aderidas ao muco do epitélio
ciliado brônquico. Por fim, efetuamos a quantificação das
mucinas estocadas nas células caliciformes do epitélio
respiratório.
RESULTADOS: O valor médio da concentração sangüínea
da ciclosporina no momento do sacrifício dos ratos foi de
1.246,57 ± 563,88 ng/ml. A transportabilidade do muco in
vitro foi estatisticamente menor (p < 0.001) no grupo
tratado com ciclosporina. Da mesma forma, houve um
decréscimo na velocidade de transporte mucociliar nos
animais imunossuprimidos em relação aos que receberam
o placebo (p = 0.02). Houve diminuição significativa na
quantidade de muco ácido (p = 0,01) e neutro (p = 0,02)
produzidos pelas células caliciformes nos animais tratados
com ciclosporina. A correlação entre a porcentagem de
muco e a transportabilidade in vitro foi positiva e
significante (r = 0.706, p < 0.001), assim como entre a
porcentagem do muco e o transporte mucociliar in situ (r
= 0.688, p = 0.001).
CONCLUSÃO: O presente estudo mostra que a
ciclosporina A age no sistema mucociliar causando um
sério prejuízo através da redução na produção de muco
ácido e neutro pelas células caliciformes como também a
diminuição da velocidade de transporte mucociliar in situ
e a transportabilidade do muco in vitro.
UNITERMOS: Ciclosporina, Transporte mucociliar,
Célula caliciforme, Mucinas.
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